A case report of psoriasis flare following immunotherapy: Report of an important entity and literature review
Immune checkpoint inhibitors, such as anti-cytotoxic T-lymphocyte–associated antigen-4 and anti-programmed death-1, are a type of cancer immunotherapy approved for late-stage malignancy treatment. However, such therapies often induce immune-related adverse events. During anti-programmed death-1 bloc...
Main Authors: | Anastasia Politi, Dimas Angelos, Davide Mauri, George Zarkavelis, George Pentheroudakis |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-01-01
|
Series: | SAGE Open Medical Case Reports |
Online Access: | https://doi.org/10.1177/2050313X19897707 |
Similar Items
-
Primary Pulmonary Malignant Melanoma: Report of an Important Entity and Literature Review
by: Christos Kyriakopoulos, et al.
Published: (2017-01-01) -
How I treat cancers of unknown primary
by: George Pentheroudakis, et al.
Published: (2019-05-01) -
The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature
by: George Zarkavelis, et al.
Published: (2020-03-01) -
Flare-up of pustular psoriasis after ustekinumab therapy: Case report and literature review
by: Ying-Xiu Dai, et al.
Published: (2018-12-01) -
Localized psoriasis herpeticum: Case report and review of literature
by: Mamatha George, et al.
Published: (2011-01-01)